ATP

Access to Pharmaceuticals

Coordinatore	ST GEORGE'S HOSPITAL MEDICAL SCHOOL    more  Organization address address: Cranmer Terrace city: LONDON postcode: SW17 0RE contact info Titolo: Dr. Nome: Paul Cognome: Craven Email: send email Telefono: +44 208 725 5012 Fax: +44 208 725 0794
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.accesstopharmaceuticals.org/
Totale costo	2˙278˙506 €
EC contributo	1˙754˙774 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2009-single-stage
Funding Scheme	CP-FP-SICA
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-10-01   -   2013-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ST GEORGE'S HOSPITAL MEDICAL SCHOOL  Organization address address: Cranmer Terrace city: LONDON postcode: SW17 0RE contact info Titolo: Dr. Nome: Paul Cognome: Craven Email: send email Telefono: +44 208 725 5012 Fax: +44 208 725 0794	UK (LONDON)	coordinator	469˙942.40
2	UNIVERSITE DE NEUCHATEL  Organization address address: FAUBOURG DU LAC 5A city: NEUCHATEL postcode: 2001 contact info Titolo: Dr. Nome: Daniel Cognome: Kraus Email: send email Telefono: +41 32 718 12 80 Fax: +41 32 718 12 81	CH (NEUCHATEL)	participant	404˙299.60
3	SOUTH AFRICAN MEDICAL RESEARCH COUNCIL  Organization address address: Francie van Zijl Drive - Parowvalley city: TYGERBERG postcode: 7505 contact info Titolo: Mr. Nome: Philip Cognome: Du Plessis Email: send email Telefono: +27 21 938 0481 Fax: +27 21 938 0564	ZA (TYGERBERG)	participant	366˙532.00
4	FUNDACAO OSWALDO CRUZ  Organization address address: AVENIDA BRASIL 4365 city: RIO DE JANEIRO postcode: 21040 900 contact info Titolo: Prof. Nome: Carlos Medicis Cognome: Morel Email: send email Telefono: -5587 Fax: -2750	BR (RIO DE JANEIRO)	participant	354˙000.00
5	INTERNATIONAL VACCINE INSTITUTE  Organization address address: "San 4-8 Bongcheon-7 dong, Kwanak gu" city: Seoul postcode: 151919 contact info Titolo: Dr. Nome: Richard Cognome: Mahoney Email: send email Telefono: 19283999255 Fax: 8228732801	KR (Seoul)	participant	160˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Access to Pharmaceuticals Equitable access to pharmaceuticals, particularly for developing countries is an essential human right. Various complex impediments hinder access, which is the subject of ongoing multidisciplinary studies. Intellectual Property and product development are two issues that can be used as tools to address the problem of access, particularly to make patented drugs more affordable and accessible. This proposal addresses three ways of accomplishing this. The first is how academic licensing practices under socially responsible stewardship can ensure that future drugs that have resulted from inventive activity in academia will be available at low cost with improved access in the future. Secondly we will research thoroughly how existing public-private or product-development partnerships are addressing the issue of altruistic development of drugs for relatively neglected populations with unmet health needs and the lessons they have for future drug development. Lastly it addresses the current state and future improvements in compulsory licensing legislative instruments to enable access through generic manufacture of patented drugs. The three routes to access have several significant aspects of overlap which provide for complementary approaches and solutions to access.'

Introduzione (Teaser)

Access to medicines and vaccines is an essential right, but barriers remain in developing countries. Recently, researchers investigated ways to make patented drugs more accessible to populations in developing countries.

Descrizione progetto (Article)

Barriers to access include high costs, resource and technology constraints, and intellectual property (IP). In addition, many promising drugs and vaccines, usually funded by private companies, do not reach market due to a lack of investment.

The EU-funded 'Access to pharmaceuticals' (http://www.accesstopharmaceuticals.org (ATP)) project aimed to address these problems and enable access to drugs. Researchers worked on improving licensing policy, analysed current product development partnerships (PDPs) and the implications of compulsory licensing.

Socially responsible licensing (SRL) refers to a policy of licensing IP in a way that promotes drug development while keeping those drugs affordable in developing countries. The project has produced a guide to SRL to promote awareness and acceptance of the concept and its underlying principles.

Case studies of PDPs revealed how IP management is changing to promote the development of new drugs. In the case of candidate dengue fever vaccines, they found that vaccine development is constrained by laws against recombinant DNA technology rather than IP issues.

Getting these vaccines to market will, however, need large financial and logistical inputs at various stages.

ATP analysed the compulsory licensing policies that are in place in several countries to promote access to generic medicines. They found that it is an effective mechanism, but requires refinement to better cater to the needs of developing countries.